The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The biosimilar market in Europe reached a value of US$ 6,735 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 25,446 Million by 2027, exhibiting at a CAGR of 22.8% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
The European biosimilar market represents the most mature in the world and continues to rally momentum. This market is expected to grow robustly in the next five years, as a number blockbuster biologics are scheduled to lose patent protection in Europe.
Biosimilars are biotherapeutic products which are similar to already licensed reference biologics, in terms of quality, safety and efficiency. Biosimilar manufacturers wait till the patent of the reference product expires and then seek approval from the regulatory authorities in order to produce their biosimilar versions. These manufacturers use the state-of-the-art technology for comparing the characteristics, such as purity, chemical identity and bioactivity, of the proposed biosimilar to its reference product. In 2005, a science-based regulatory framework was established in the European Union (EU) for ensuring the production of high-quality biosimilars. Later in 2006, the European Medicines Agency (EMA) approved the first biosimilar medicine, Omnitrope. Since then, a number of biosimilars belonging to various therapeutic classes have been approved in Europe.
Biosimilars Market in Europe: Drivers
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the biosimilar market in Europe, along with forecasts at the regional and country level from 2022-2027. Our report has categorized the market based on molecule, indication and manufacturing type.
Breakup by Country:
Country-wise, the market has been segmented into Italy, Germany, United Kingdom, France, Spain and Rest of Europe.
Breakup by Molecule:
The report has analysed the market on the basis of molecule. The market has been segmented into Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, etc.
Breakup by Indication:
The report has also analysed the market on the basis of indication. Other major indications include oncology, autoimmune diseases, blood disorders, growth deficiency, diabetes, female infertility etc.
Breakup by Manufacturing Type:
On the basis of manufacturing type, the report has segmented the market into in-house manufacturing and contract manufacturing.
Some of the leading players operating in the European biosimilars market include:
This report provides a deep insight into the European biosimilars market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the European biosimilars market in any manner.
|Base Year of the Analysis||2021|
|Segment Coverage||Molecule, Indication, Manufacturing Type, Country|
|Companies Covered||Italy, Germany, United Kingdom, France, Spain, Rest of Europe|
|Companies Covered||Novartis, Pfizer, Teva, Celltrion, Samsung Bioepis, Amgen, Apotex, Ratiopharm, Mylan, Merck Sharp & Dohme, Eli Lilly, Accord Healthcare Ltd, Boehringer Ingelheim, Hexal Ag, and Stada Arzneimittel Ag|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License $ 2699
Five User License $ 3699
Corporate License $ 4699
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The biosimilar market in Europe was valued at US$ 6,735 Million in 2021.
We expect the biosimilar market in Europe to exhibit a CAGR of 22.8% during 2022-2027.
The rapid patent expiration of various blockbuster biologics, coupled with the increasing awareness
pertaining to the efficiency and safety of biosimilars, is currently driving the biosimilar market in
The sudden outbreak of the COVID-19 pandemic had led to the delayed clinical trials for biosimilars
due to the rising focus on the production of effective vaccines against coronavirus infection, thereby
negatively impacting the biosimilar market in Europe.
Based on the molecule, the biosimilar market in Europe can be bifurcated into infliximab, insulin
glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, follitropin alfa, and
adalimumab. Currently, infliximab holds the majority of the total market share.
Based on the indication, the biosimilar market in Europe has been divided into auto-immune
diseases, blood disorder, diabetes, oncology, growth deficiency, and female infertility. Among these,
auto-immune diseases currently exhibit a clear dominance in the market.
Based on the manufacturing type, the biosimilar market in Europe can be segmented into in-house
manufacturing and contract manufacturing. Currently, in-house manufacturing represents the
On a regional level, the market has been classified into Italy, Germany, United Kingdom, France,
Spain, and rest of Europe, where Italy dominates the biosimilar market in Europe.
Some of the major players in the biosimilar market in Europe include Novartis, Pfizer, Teva, Celltrion,
Samsung Bioepis, Amgen, Apotex ,Ratiopharm, Mylan, Merck Sharp & Dohme, Eli Lilly, Accord
Healthcare Ltd, Boehringer Ingelheim, Hexal Ag, Stada Arzneimittel Ag, etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at